“We do not foresee the FDA approving any drugs for the improvement of non-LDL lipid parameters in the near future – at least not without a long outcomes study. Non-LDL lipids would need formal validation for expedited clinical development.”
– Ritu Baral, analyst, Canaccord Genuity, in a research note on the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voting against an application for Amarin Pharmaceuticals Inc.’s Vascepa

“It was a competitive process. I’m pleased with the economic outcome, but also pleased Astrazeneca is the winner here, because it has a tremendous amount of capability and expertise in the area.”
– Stephen Evans-Freke, chairman, Spirogen plc, on its acquisition by Astrazeneca plc

“One reason why this research is so important is that it represents a completely original approach to how neurodegenerative diseases are studied, looking at what actually goes wrong in the brain cells. We were extremely excited when we saw the treatment stop the disease in its tracks and protect brain cells, restoring some normal behaviors and preventing memory loss in the mice.”
– Giovanna Mallucci, program leader, Medical Research Council Toxicology Unit, Leicester, UK, on an oral drug that inhibits a metabolic pathway in the brain called the unfolded protein response